M. Veslemes

发表

Expression of EGF, TGF-alpha and EGFR in squamous cell lung carcinomas.

V. Gorgoulis, A. Karameris, B. Ozanne, 1992, Anticancer research.

Epidermal growth factor receptor expression in squamous cell lung carcinomas: An immunohistochemical and gene analysis in formalin-fixed, paraffin-embedded material

V. Gorgoulis, A. Giatromanolaki, A. Karameris, 2005, Virchows Archiv A.

Molecular and immunohistochemical study of class I growth factor receptors in squamous cell lung carcinomas.

V. Gorgoulis, V. Gorgoulis, A. Karameris, 1995, Pathology, research and practice.

Phase II study of cisplatin-combined schedules as second-line chemotherapy in patients with non-small cell lung cancer.

G. Stathopoulos, D. Antoniou, J. Dimitroulis, 2005, Anticancer research.

Second-line chemotherapy with cisplatin-ifosfamide in patients with ovarian cancer previously treated with carboplatin-cyclophosphamide.

N. Tsavaris, C. Kosmas, A. Polyzos, 1999, Journal of chemotherapy.

C-erbB-2 oncoprotein expression in operable non-small cell lung cancer.

K. Gatter, V. Gorgoulis, C. Kittas, 1996, Anticancer research.

Cisplatin plus etoposide chemotherapy followed by thoracic irradiation and paclitaxel plus cisplatin consolidation therapy for patients with limited stage small cell lung carcinoma.

V. Georgoulias, E. Tsaroucha, C. Kouroussis, 2006, Lung cancer.

The smoking-cessation promotion practices of physician smokers in Greece.

A. Polyzos, N. Katsilambros, M. Veslemes, 2009, Journal of cancer education : the official journal of the American Association for Cancer Education.

Treatment of Lower Respiratory Tract Infections with Amoxycillin/Clavulanic Acid in Adults

J. Jordanoglou, M. Veslemes, G. Tatsis, 1993, The Journal of international medical research.

Alternate paclitaxel-gemcitabine and paclitaxel-vinorelbine biweekly administration in non-small cell lung cancer patients: a phase II study.

G. Stathopoulos, D. Antoniou, J. Dimitroulis, 2006, Anticancer research.

Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study

I. Vlachonikolis, K. Syrigos, V. Georgoulias, 2004, British Journal of Cancer.

Expression of p16INK4A and alterations of the 9p21‐23 chromosome region in non‐small‐cell lung carcinomas: Relationship with tumor growth parameters and ploidy status

V. Gorgoulis, A. Kotsinas, T. Liloglou, 2000, International journal of cancer.

Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial.

V. Georgoulias, G. Samonis, D. Mavroudis, 2001, Lung cancer.

Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression.

T. Halazonetis, V. Gorgoulis, A. Kotsinas, 1998, The American journal of pathology.

Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer.

Ioannis Karydis, I. Karydis, G. Stathopoulos, 2006, Lung cancer.

A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer.

V. Georgoulias, D. Mavroudis, S. Kakolyris, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III study comparing sequential versus alternate administration of cisplatin-etoposide and topotecan as first-line treatment in small cell lung cancer.

S. Agelaki, D. Mavroudis, V. Georgoulias, 2010, Anticancer research.

Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a Phase III Trial of the Hellenic Oncology Research Group.

D. Mavroudis, V. Georgoulias, M. Ignatiadis, 2005, Clinical lung cancer.

Chemotherapy of non small cell lung cancer. A prospectively randomized study of cisplatin-etoposide versus cisplatin-mitomycin-vinblastine.

K. Dardoufas, T. Dosios, N. Tsavaris, 1997, Journal of chemotherapy.

Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small-cell lung cancer: a randomized phase III trial.

K. Vergos, S. Loukides, G. Stathopoulos, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

A Single-Blind Crossover Study of Two Different Slow Release Theophylline Preparations

M. Gaga, J. Jordanoglou, M. Veslemes, 1988, The Journal of international medical research.

Mesothelioma: treatment and survival of a patient population and review of the literature.

G. Stathopoulos, D. Antoniou, J. Dimitroulis, 2005, Anticancer research.

A multicenter phase II study of the combination of gemcitabine and docetaxel in previously treated patients with small cell lung cancer.

V. Georgoulias, K. Syrigos, N. Tzanakis, 2004, Lung cancer.

Sequential administration of cisplatin-etoposide followed by topotecan in patients with extensive stage small cell lung cancer. A multicenter phase II study.

S. Agelaki, D. Mavroudis, V. Georgoulias, 2003, Lung cancer.

Cisplatin-etoposide alternating with topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study.

D. Mavroudis, N. Tzanakis, G. Samonis, 2002, Lung cancer.

Immunohistochemical and molecular evaluation of the mdm-2 gene product in bronchogenic carcinoma.

C. Kittas, V. Gorgoulis, G. Rassidakis, 1996, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial

I. Vlachonikolis, V. Georgoulias, A. Rapti, 2001, The Lancet.

A multicenter randomized phase III study comparing paclitaxel-cisplatin-etoposide (TEP) versus cisplatin-etoposide (EP) as front-line treatment in patients with small cell lung cancer (SCLC)

G. Samonis, N. Ziras, V. Georgoulias, 2000 .

Optimal duration of chemotherapy in small cell lung cancer: a randomized study of 4 versus 6 cycles of cisplatin-etoposide.

A. Polyzos, J. Dimitroulis, P. Latsi, 1998, Journal of chemotherapy.

Amifostine reduces radiochemotherapy-induced toxicities in patients with locally advanced non-small cell lung cancer.

M. Synodinou, D. Antonadou, M. Veslemes, 2003, Seminars in oncology.

Outcome of patients with brain metastases after combined modality therapy in small cell lung cancer (SCLC): a retrospective study.

A. Polyzos, J. Dimitroulis, P. Latsi, 1995, Journal of chemotherapy.

Response to radiotherapy in brain metastases and survival of patients with non-small cell lung cancer.

G. Stathopoulos, D. Antoniou, J. Dimitroulis, 2005, Oncology reports.

THE LUNG CANCER PARADOX: TIME FOR ACTION in Scotland Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial

A. Gregor, D. Brewster, R. Milroy, 2002 .